Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

R), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint. Importantly, the trial also confirmed the positive results seen in the first Phase III trial with microplasmin. The results of the second Phase III trial (TG-MV-007) were presented for the first time at the American Society of Retina Specialists (ASRS) Annual Meeting by Dr. J. Michael Jumper (West Coast Retina and Medical Group and California Pacific Medical Center, California, USA). The trial recruited 326 patients at 48 centers in Europe and the U.S.

The detailed positive results from the first Phase III trial in the microplasmin MIVI-TRUST program (TG-MV-006) were presented at the World Ophthalmology Congress in Berlin in June 2010. The pooled results of both trials will be presented at the upcoming EURETINA (European Society of Retina Specialists) Congress in Paris, France, on September 4 by Prof. Peter Stalmans (University Hospitals Leuven, Belgium).

In his presentation at ASRS, Dr. Jumper highlighted that the TG-MV-007 study had met its primary endpoint, with 25.3% of the 245 microplasmin treated patients achieving resolution of their VMA at 28 days, compared to 6.2% of the 81 patients who received a placebo injection, a highly statistically significant result (p=0.001). In patients without epiretinal membrane, microplasmin was shown to be even more effective with 34.5% of patients seeing resolution of their VMA at 28 days, compared to 6.4% of placebo treated patients. Epiretinal membrane is a layer of scar tissue which builds up on the macula, making it more difficult to achieve resolution of VMA without surgical intervention. Epiretinal membrane can be easily identified using Optical Coherence Tomography (OCT).


'/>"/>
SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today provided an ... and  Spherix v. Uniden , Case No. 3:13-cv-03496-M, ... the Northern District of Texas ... Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the United ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
(Date:3/29/2015)... , March 29, 2015  Caris Life Sciences® ... which Caris Molecular Intelligence®, the company,s panomic, comprehensive ... differences between several rare and difficult to treat ... have the potential to improve patient outcomes. These ... at the Society of Gynecologic Oncology (SGO) 2015 ...
(Date:3/29/2015)... March 29, 2015 As a symbol ... required by our pharmaceutical manufacturing clients, Whitehouse Laboratories is ... of the Berkenstock Race Team for the 2015 race ... only speed, but a strong sense of precision and ... lead to success in the quality control testing laboratory. ...
Breaking Biology Technology:Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... June 2 Dendreon Corporation (Nasdaq: DNDN ) today announced ... Company,s Board of Directors.  Dr. Stump is currently executive vice president of ... where he has been a member of its management committee since 1999. ... "We welcome Dave to ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today announced the promotion ... as the company,s Vice President, Chief Accounting Officer since joining BioMed in ... , "I am ... Griffin , BioMed,s President and Chief Operating Officer. "Greg has been an integral ...
... June 2 NeoGenomics, Inc. (OTC ... the Sixth Annual Noble Financial Equity Conference at 12:30 ... at the Seminole Hard Rock Hotel in Hollywood, FL. ... will give a presentation regarding NeoGenomics, market positioning, financial performance, ...
Cached Biology Technology:Dendreon Announces Election of Dr. David C. Stump to Board of Directors 2Dendreon Announces Election of Dr. David C. Stump to Board of Directors 3BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer 2BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer 3NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3
(Date:3/20/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces its ... of the products featured in 2015 "I Want That" ... PM EST on the DIY Network.   ... Vegas , site of the 2015 International CES ...
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
(Date:3/17/2015)... March 17, 2015 MedNet Solutions ... in clinical study management systems, is pleased to ... at ARENA,s Outsourcing in Clinical Trials Southeast conference ... provides an excellent forum for MedNet to showcase ... affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... that restoring a gene often silenced in lung cancer causes ... new strategy for treating the disease. , The research ... or silenced in a large majority of lung cancers, and ... pancreas. The work was led by scientists at The Ohio ...
... Researchers at the Salk Institute for Biological Studies discovered ... strands of DNA to protect the integrity of chromosomes. ... question that has long puzzled scientists. , The natural ... DNA that a cell's repair machinery is designed to ...
... have discovered the presence of functional ion channels in ... like electrical wires and permit ESCs, versatile cells that ... of the body, to conduct and pass along electric ... these channels in implanted cells, derived from stem cells, ...
Cached Biology News:Restoring silenced suppressor gene kills lung-cancer cells 2Normal chromosome ends elicit a limited DNA damage response 2Stem cells' electric abilities might help their safe clinical use 2
... is used for the synthesis of 5' ... reactions. Substitution of cap analog for a ... in vitro transcription reaction results in the ... large fraction of the transcripts. Capped mRNAs ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... Description: Beta-Agarase is useful in recovering ... agarose. Beta-Agarase digests the agarose into ... Properties: Heat Inactivation: 65C, 15 min ... 6.5 Purity: Tested for contaminating endonucleases, ...
... A modified nucleotide structure called ... 5?-end of most naturally-occurring eukaryotic mRNAs ... Cap Analog for a portion of ... vitro transcription reaction results in the ...
Biology Products: